Biotech Showcase Interviews
Faron CEO Markku Jalkanen outlines ambitions for lead programs
Armed with an FDA approval for its Traumakine program and the expectation of a pivotal Phase III readout in the summer of 2018, Faron president and CEO Marrku Jalkenen explains to Scrip his expectations for the potential acute respiratory distress syndrome treatment.